Table 4.

Average squared error and R-square for the final model and models investigated in sensitivity analyses on the derivation and validation sets.

	Derivation set		Validation set
Models	ASE	R-square	ASE
Final model*	0.67	0.47	0.91
Base model#	0.76	0.40	0.92
ANRS 2013§	0.72	0.44	0.94
HIVdb 7.0§	0.73	0.43	0.95
REGA 9.1.0§	0.74	0.42	0.91
Sensitivity analyses on the derived model
10-fold	0.67	0.47	0.91
25 copies/mL	0.77	0.41	1.04
2 ways interactions	0.68	0.48	0.91
GSS HIVdb	0.68	0.46	0.93

^*Least squared estimation (LSE) using the model including the derived weighted darunavir mutations, baseline CD4 and HIV-1 RNA and GSS of the accompanying drugs (according to ANRS 2013 interpretation)

^#LSE using the final model without the derived weighted darunavir mutations (i.e. using only baseline CD4 and HIV-1 RNA and GSS of the accompanying drugs)

^§LSE models including the available darunavir genotypic interpretations, baseline CD4, HIV-1 RNA and GSS of the accompanying drugs

10-fold = 10-fold cross validation was used instead of 5-fold

25 copies/mL =undetectable value replaced with 25 copies/mL

2-way interactions = significant 2-way interactions between mutations terms retained in the final model

GSS HIVdb = the final model is adjusted for the GSS of the drugs accompanying darunavir computed according to HIVdb 7.0 instead of ANRS 2013.

Accuracy = percentage of cases correctly classified